The Optimal Biological Therapy for Conversion in Patients with RAS-Wild-Type Colorectal Cancer and Unresectable Liver Metastases
In brief
Anti-EGFR therapy linked to liver resection in 67% of patients
In a single-centre cohort of 101 patients with RAS-wild-type colorectal cancer and unresectable liver metastases, anti-EGFR treatment was associated with a higher resection rate than bevacizumab, 67% versus 46%, and longer progression-free survival. Overall survival did not differ significantly, and similar severe toxicity rates do not resolve which treatment is best; randomized studies are needed to confirm the findings.
- Journal
- Cancers (Q1)
- Published
- 29 October 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Miljana Džunić, Ivan Petković, Ana Cvetanović, Miroslav Stojanović, Ivan Nikolić, Marina Marković, et al.
- PMID
- 43026811
- DOI
- 10.3390/cancers18213489
Why clinicians should know about it
- Picked for Surgical Oncology (top studies of the week, 15 November 2026): Conversion treatment associated with liver metastasis resection rates
Abstract
Background/Objectives: Resection is the treatment goal in unresectable liver-limited metastatic colorectal cancer (mCRC). Anti-VEGF and anti-EGFR antibodies are effective in RAS wild-type mCRC, but the better option for conversion is unclear. We compared their efficacy and tolerability as first-line treatment. Methods: In this prospective, single-centre cohort study, patients with RAS-wild-type mCRC and unresectable liver metastases received cetuximab or panitumumab (anti-EGFR) or bevacizumab (anti-VEGF) with FOLFOX or FOLFIRI. We compared the overall response rate (ORR), depth of response (DoR), resection rate (RR), progression-free survival (PFS), overall survival (OS) and toxicity, using Cox regression adjusted for baseline covariates. Results: Of 101 patients, 51 received anti-EGFR therapy and 50 bevacizumab. Anti-EGFR therapy achieved a higher ORR (70.6% vs. 50.0%; p = 0.034), deeper response (47.2% vs. 33.7%; p = 0.004) and higher RR (66.7% vs. 46.0%; p = 0.036). The median PFS was longer (12.1 vs. 8.5 months; adjusted HR 0.48, 95% CI 0.29-0.78; p = 0.003), whereas the median OS did not differ significantly (30.4 vs. 25.5 months; p = 0.382). Grade 3/4 toxicity was similar (35.3% vs. 22.0%; p = 0.187). Conclusions: Anti-EGFR therapy was associated with higher response and resection rates and longer PFS and may be considered when conversion is the aim; these single-centre, non-randomised findings require confirmation in randomised studies.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.